98%
921
2 minutes
20
Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals - including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871378 | PMC |
http://dx.doi.org/10.1590/S1677-5538.IBJU.2015.0365 | DOI Listing |
Cureus
August 2025
General Medicine, Universidad de Ciencias Médicas (UCIMED), San José, CRI.
Many patients with injuries to their central nervous system, especially those who have had a stroke or a spinal cord injury, have neurogenic voiding dysfunction. It happens when patients can't control their bladder voluntarily, which can make them feel urgency, experience leaks, or have trouble emptying their bladder. If not treated right away, it can cause infections, damage to the bladder, or even kidney problems over time.
View Article and Find Full Text PDFLow Urin Tract Symptoms
September 2025
Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Objectives: This study aims to examine the association of systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with the prevalence of overactive bladder (OAB).
Methods: This cross-sectional study analyzed data from 22,343 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (2005-2018). We applied weighted multivariate logistic regression, restricted cubic spline (RCS) regression, subgroup, and sensitivity analyses to assess the associations between SII, NLR, and OAB.
Acta Neurol Belg
September 2025
Department of Neurology, Kutahya Health Sciences University, Kütahya, Turkey.
Background: Overactive bladder (OAB) symptoms significantly affect the independence and quality of life in patient with multiple sclerosis (PwMS) by limiting daily activities. This study aimed to explore differences in fear of falling (FoF), gait, dual-task performance, and self-perceived impact of disease among PwMS with and without OAB.
Method: Participants were divided into two groups based on their Overactive Bladder Questionnaire (OAB-V8) scores: OAB (score ≥ 8) and non-OAB (score < 8).
Anal Bioanal Chem
September 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.
The recent approval of a fixed-dose combination of silodosin (SOD) and solifenacin succinate (SOF) for overactive bladder syndrome has created a need for innovative analytical approaches enabling their simultaneous quantification. In this work, seven novel, eco-friendly, and cost-efficient spectrophotometric methods were developed for the concurrent determination of SOD and SOF. These methods overcome the limitations of conventional techniques by eliminating the need for complex instrumentation, labor-intensive procedures, and large volumes of hazardous organic solvents, offering a sustainable and accessible analytical alternative.
View Article and Find Full Text PDFUrology
September 2025
Sumitomo Pharma America, Inc., Marlborough, MA.
Objective: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes.
Methods: Men >45 years with OAB receiving pharmacotherapy for BPH were randomly assigned 1:1 to vibegron 75 mg or placebo for 24 weeks. Participants completed bladder diaries assessing changes in micturition frequency, nocturia, and urge urinary incontinence (UUI); International Prostate Symptom Score (IPSS); and OAB questionnaire (OAB-q).